PCVX shareholder plans 2,250-share stock sale

A holder of PCVX common stock, James Wassil, has filed to sell 2,250 shares through UBS Financial Services on the NASDAQ on August 3, 2026, following an exercise of stock options for cash.

Rhea-AI Filing Summary

A holder of PCVX common stock, James Wassil, has filed to sell 2,250 shares through UBS Financial Services on the NASDAQ on August 3, 2026, following an exercise of stock options for cash. The filing also lists prior sales over the past three months: 2,250 shares of common stock on June 1, 2026 for $111,416.62, and 2,250 shares on July 1, 2026 for $126,735.98, with the planned sale valued at $121,477.50 based on the stated aggregate market value.

Key Figures

Planned shares to be sold: 2,250 shares Planned sale value: $121,477.50 June 1, 2026 sale: 2,250 shares; $111,416.62 +2 more

5 metrics

Planned shares to be sold 2,250 shares Common stock sale expected on August 3, 2026

Planned sale value $121,477.50 Aggregate market value for 2,250 shares for August 3, 2026 sale

June 1, 2026 sale 2,250 shares; $111,416.62 Common stock sold on June 1, 2026

July 1, 2026 sale 2,250 shares; $126,735.98 Common stock sold on July 1, 2026

Planned sale date 08/03/2026 Date associated with planned NASDAQ sale via UBS Financial Services

Key Terms

Exercise of stock options, aggregate market value, broker

3 terms

Exercise of stock options financial

"Common | 08/03/2026 | Exercise of stock options | Issuer"

aggregate market value financial

"Common | UBS Financial Services, Inc. ... | 2250 | 121477.50"

Aggregate market value is the combined price you would pay to buy all outstanding shares of a company or all companies in a group at current market prices — essentially the sum of each stock’s market capitalization. It matters to investors because it shows the overall size and weight of an investment or sector (like the total cost to buy every piece of a puzzle), helps compare scale across companies or markets, and influences index composition and risk exposure.

broker financial

"Common | UBS Financial Services, Inc. ... NASDAQ"

A broker is a licensed professional or firm that helps investors buy and sell financial assets by executing trades on their behalf, acting like a marketplace agent or matchmaker between buyers and sellers. Brokers matter to investors because they provide access to markets, handle order execution and paperwork, and can offer research or advice—services that affect trade speed, costs, and the quality of investment decisions.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What stock sale is being planned for PCVX under this filing?

The filer plans to sell 2,250 shares of PCVX common stock on August 3, 2026 through UBS Financial Services on the NASDAQ, following a cash exercise of stock options.

What is the reported value of the planned PCVX share sale?

The planned sale of 2,250 PCVX common shares is valued at an aggregate market value of $121,477.50, as reported in connection with the anticipated transaction dated August 3, 2026.

What PCVX shares has James Wassil sold in the past three months?

James Wassil reported selling 2,250 PCVX common shares on June 1, 2026 for $111,416.62 and another 2,250 shares on July 1, 2026 for $126,735.98.

How many PCVX shares in total are referenced across recent and planned sales?

The filing references three blocks of 2,250 PCVX common shares each: one planned sale on August 3, 2026, and two prior sales on June 1 and July 1, 2026.

What is the method of acquisition for the PCVX shares to be sold?

The 2,250 PCVX common shares to be sold on August 3, 2026 are tied to an exercise of stock options, with the exercise described as being for cash.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/03/2026 - 04:15 PM Accepted by SEC EDGAR 08/03/2026 - 04:14 PM Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001813798
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	Vaxcyte, Inc.
SEC File Number	001-39323
Address of Issuer	825 INDUSTRIAL ROAD, STE. 300 SAN CARLOS CALIFORNIA 94070
Phone	650-837-0111
Name of Person for Whose Account the Securities are To Be Sold	Wassil Jim
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	UBS Financial Services, Inc. 11 Madison Ave 4th Floor New York NY 10010	2250	121477.50	144397682	08/03/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	08/03/2026	Exercise of stock options	Issuer			2250	08/03/2026	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
James Wassil 825 INDUSTRIAL ROAD, STE. 300 SAN CARLOS CA 94070	Common	06/01/2026	2250	111416.62
James Wassil 825 INDUSTRIAL ROAD, STE. 300 SAN CARLOS CA 94070	Common	07/01/2026	2250	126735.98

144: Remarks and Signature

Remarks
Date of Notice	08/03/2026
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	12/09/2025
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/ UBS Financial Services Inc, as attorney-in-fact for James Wassil
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)